These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

172 related articles for article (PubMed ID: 404869)

  • 1. Determination of factor VIII-related antigen using commercial antisera.
    Chediak J; Maxey B; Telfer M
    Am J Clin Pathol; 1977 May; 67(5):462-9. PubMed ID: 404869
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Platelet-bound ristocetin aggregation factor in normal subjects and patients with von Willebrand's disease.
    Green D; Potter EV
    J Lab Clin Med; 1976 Jun; 87(6):976-86. PubMed ID: 778313
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Acquired von Willebrand syndrome with inhibitors both to factor VIII clotting activity and ristocetin-induced platelet aggregation.
    Stableforth P; Tamagnini GL; Dormandy KM
    Br J Haematol; 1976 Aug; 33(4):565-73. PubMed ID: 1087568
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Re-evaluation of plasmas from patients previously diagnosed as having von Willebrand's disease with the factor VIII-related antigen and ristocetin cofactor assay.
    Ness PM; Hymas PG; Perkins HA
    Am J Clin Pathol; 1979 Jan; 71(1):26-30. PubMed ID: 311154
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Dissociation between factor VIII (activity and antigen) and ristocetin-induced platelet aggregation in von Willebrand's disease.
    Barbui T; Dini E
    Acta Haematol; 1975; 53(1):44-8. PubMed ID: 807074
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Quantitative assay of a plasma factor deficient in von Willebrand's disease that is necessary for platelet aggregation. Relationship to factor VIII procoagulant activity and antigen content.
    Weiss HJ; Hoyer LW; Rickles FR; Varma A; Rogers J
    J Clin Invest; 1973 Nov; 52(11):2708-16. PubMed ID: 4542944
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Electrophoretic heterogeneity of normal factor VIII/Von Willebrand protein, and abnormal electrophoretic mobility in patients with Von Willebrand's disease.
    Sultan Y; Simeon J; Caen JP
    J Lab Clin Med; 1976 Feb; 87(2):185-94. PubMed ID: 1082003
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Defective ristocetin-induced platelet aggregation in von Willebrand's disease and its correction by factor VIII.
    Weiss HJ; Rogers J; Brand H
    J Clin Invest; 1973 Nov; 52(11):2697-707. PubMed ID: 4201262
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Detection of heterozygotes in both parents of homozygous patients with Von Willebrand's disease.
    Sultan Y; Simeon J; Caen JP
    J Clin Pathol; 1975 Apr; 28(4):309-16. PubMed ID: 805164
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Infusion of human and canine factor VIII in dogs with von Willebrand's disease: studies of the von Willebrand and factor VIII synthesis stimulating factors.
    Bouma BN; Dodds WJ; van Mourik JA; Sixma JJ; Webster WP
    Scand J Haematol; 1976 Oct; 17(4):263-75. PubMed ID: 825957
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Factor-VIII-related antigen: measurement by enzyme immunoassay.
    Bartlett A; Dormandy KM; Hawkey CM; Stableforth P; Voller A
    Br Med J; 1976 Apr; 1(6016):994-6. PubMed ID: 1083757
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Diagnosis of von Willebrand's disease].
    Baklaja R; Stojimirović E; Kezić J; Cuperlović K; Jovanović B; Cvetković V; Rasović N; Stajić M
    Bilt Hematol Transfuz; 1977; 5(3-4):41-61. PubMed ID: 307953
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The relationship of the properties of antihemophilic factor (factor VIII) that support ristocetin-induced platelet agglutination (factor VIIIR:RC) and platelet retention by glass beads as demonstrated by a monoclonal antibody.
    Ogata K; Saito H; Ratnoff OD
    Blood; 1983 Jan; 61(1):27-35. PubMed ID: 6401215
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Precipitating anti-VIII:C antibodies in two patients with haemophilia A.
    Lavergne JM; Meyer D; Girma JP; Larrieu MJ
    Br J Haematol; 1982 Jan; 50(1):135-46. PubMed ID: 6798988
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The defect in hemophilic and von Willebrand's disease plasmas studied by a recombination technique.
    Cooper HA; Wagner RH
    J Clin Invest; 1974 Nov; 54(5):1093-9. PubMed ID: 4213756
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Platelet function and immunologic parameters in von Willebrand's disease following cryoprecipitate and factor VIII concentrate infusion.
    Chediak JR; Telfer MC; Green D
    Am J Med; 1977 Mar; 62(3):369-76. PubMed ID: 300224
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Relationship between ristocetin-induced platelet aggregation and factor VIII (activity and antigen) in v. Willebrand's disease.
    Barbui T; Battista R; Dini E
    Blut; 1974 Oct; 29(4):260-4. PubMed ID: 4547631
    [No Abstract]   [Full Text] [Related]  

  • 18. [Enzyme immunoassay of factor VIII-related antigen with observation in patients with von Willebrand's disease and hemophilia A (author's transl)].
    Okuda T; Masuyama H; Tanigawa T; Narihiro N; Fujimura Y; Takase T; Mikami S; Yoshioka A; Fukui H
    Rinsho Ketsueki; 1980 Jul; 21(7):946-52. PubMed ID: 6775115
    [No Abstract]   [Full Text] [Related]  

  • 19. Recent advances in haemophilia and von Willebrand's disease.
    Ekert H; Firkin BG
    Vox Sang; 1975; 28(6):409-21. PubMed ID: 125001
    [No Abstract]   [Full Text] [Related]  

  • 20. Absence of ristocetin aggregation factor from the skin of a patient with von Willebrand's disease.
    Potter EV; Chediak J; Green D
    Lancet; 1976 Mar; 1(7958):514-5. PubMed ID: 55785
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.